To investigate potential enhancements in treatment efficacy for HR-positive HER2-positive BC, we conducted in vitro studies assessing the impact of CDK4/6 inhibitors combined with HER2-targeted therapy on tumor cell behavior. This evidence concerns the gene ERBB2 and neoplasm.